Sign inJoin waitlistJoin the waitlist

Eric Schafer

Director, Pediatric Hematology-Oncology Fellowship Program · Baylor College of Medicine

Credentials: · · ·

History

Baylor College of Medicine
Present
Baylor College of Medicine
Present

Pediatric Hematology Oncology
Johns Hopkins University School of Medicine
2006–2009
Pediatrics
Children's Hospital of Philadelphia
2003–2006
Baylor College of Medicine
1999–2003

Research

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Journal of Clinical Oncology · 2022 · 138 citations
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting
Blood · 2010 · First of 8 authors · 86 citations
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology…
Pediatric Blood & Cancer · 2020 · First of 14 authors · 64 citations

Deepa Bhojwani
8 papers
Alan Wayne
7 papers
BC
Bill Chang
6 papers
Julienne Brackett
6 papers
Lauren Pommert
6 papers
Karen Rabin
5 papers
NG
Nathan Gossai
5 papers
Alexandra Stevens
4 papers
AC
Ashley Chavana
4 papers
Jennifer Foster
4 papers
Mary Shapiro
4 papers
Maureen O'Brien
4 papers

Grants

NCI Research Specialist (Clinician Scientist) Award
National Cancer Institute · R50
Contact PI · $882.5K · Baylor College of Medicine
2025–2030

Clinical trials

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2014–2018
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Study chair · Recruiting · Phase 1
Allterum Therapeutics, Inc
2026–2028
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032